Skip to content
Study at a glance
| Characteristics |
Theoretical
Peer reviewed
|
| Key finding |
This study proposes novel indoline derivatives as 5-HT2A agonists for treating psychosis and CNS disorders. |
Abstract
Novel Indoline Derivatives Serotonergic Psychedelic Agents as 5‑HT2A Agonists for Treating Psychosis, Mental Illness and CNS Disorders.
Related reading
-
Novel Indoline Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness and CNS Disorders.
ACS Med Chem Lett
January 23, 2025
3 citations
via PubMed Central
-
Novel Indole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness, and CNS Disorders.
ACS medicinal chemistry letters
June 12, 2025
4 citations
via PubMed
-
Novel 3-Cycloaminoindole Compounds as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness, and CNS Disorders.
ACS Med Chem Lett
January 4, 2025
via PubMed Central
-
Novel 3-Pyrrolidineindole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis and Mental Illnesses Such as Depression and Post-Traumatic Stress Disorder.
ACS medicinal chemistry letters
January 9, 2025
7 citations
via PubMed
-
Novel Compounds as 5-HT2A Agonists for Treating Mental Illness or CNS Disorders.
ACS Med Chem Lett
February 11, 2025
via PubMed Central